je.st
news
Tag: gileads
Gilead's hepatitis C drugs largely cost-effective in US: study
2015-03-17 04:45:41| Biotech - Topix.net
New hepatitis C drugs that shorten treatment times are largely cost-effective despite their hefty U.S. price tags, according to two new analyses. The widespread use of a combination of drugs that include Gilead Sciences Inc's Sovaldi, known generically as sofosbuvir, will nonetheless be a significant cost for the U.S. healthcare system, researchers wrote.
$10 copy of Gilead's blockbuster Sovaldi appears in Bangladesh
2015-03-09 08:23:54| Biotech - Topix.net
A $10 version of Sovaldi, the Gilead Sciences Inc. hepatitis C treatment that sells for $1,000 a pill in the U.S., is now available in Bangladesh and could make its way to other parts of the world where the U.S. company doesn't have patents. Incepta Pharmaceuticals Ltd. doesn't have a license from Gilead and its version was launched last month, said managing director Abdul Muktadir.
Tags: copy
appears
bangladesh
blockbuster
UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment
2015-01-29 03:19:07| Beverages - Topix.net
UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc. Gilead and AbbVie have been battling for hepatitis C market share since the approval in December for an AbbVie drug that challenges Gilead's blockbusters. Insurers and pharmacy benefit managers have been striking deals for preferred or exclusive status in exchange for discounts for 2015.
Tags: update
treatment
preferred
backs
Gilead's India patent snag may spur low-cost Sovaldi copies
2015-01-20 22:41:19| Biotech - Topix.net
The Indian patent office's rejection of a key patent for Gilead Sciences' Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country. The New Delhi patent office this week rejected one of the patents for Sovaldi on the grounds that it "lacks novelty" and lacks an inventive step.
Tags: india
copies
patent
spur
Gilead's India Patent Snag May Spur Low-Cost Sovaldi Copies
2015-01-16 02:44:37| Biotech - Topix.net
The Indian patent office's rejection of a key patent for Gilead Sciences' Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country. The New Delhi patent office this week rejected one of the patents for Sovaldi on the grounds that it "lacks novelty" and lacks an inventive step.
Tags: india
copies
patent
spur